Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01147081 | Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2010/2011 | PHASE3 | COMPLETED | 142 | — | — | Jun 1, 2010 | Jul 1, 2010 | Jan 5, 2012 | 3 | Germany |
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BEGRIVAC | BIOLOGICAL | 126 healthy subjects enrolled to receive, in open-label manner, one dose of Begrivax (influenza vaccine) |
Inclusion Criteria: 1. Male and female volunteers of 18 years of age and older, mentally competent, willing and able to give written informed consent prior to study entry; 2. Individuals able to comply with all the study requirements; 3. Individuals in good health as determined by medical history, ...